WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--BASi continues to expand their bioanalytical services in the area of large molecule bioanalysis; protein-based and oligonucleotide-based therapeutics. BASi offers ligand binding assays (LBA) which are ideal for macromolecular drug therapeutics, immunogenicity screening and biomarkers in biological matrices. Enzyme immunoassays (EIA) or enzyme-linked immunosorbent assay (ELISA)-based applications are our primary tools for these services.
